Investors

OvaScience is a global fertility company dedicated to improving treatment options for women around the world.

OVAS (Common Stock)
Price & Exchange
$1.44
NASDAQ
Change (%)
 Stock is Up 0.07 (5.11%)
Volume
151,051
11/20/17      3:27 p.m. ET

Minimum 20 minute delay
Refresh quote

Corporate Governance - Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.
Chairperson Chairperson Committee Member Member Financial Expert Financial Expert
 Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee
Rich Aldrich 
Rich Aldrich
Co-Founder and Chairman


Mr. Aldrich is a Co-Founder of OvaScience and is Chairman of the company’s Board of Directors. Mr. Aldrich is also a Founder and Partner of Longwood Fund, which founds and invests in biotechnology companies. Mr. Aldrich has co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008), Concert Pharmaceuticals, Alnara Pharmaceuticals (acquired by Eli Lilly in 2010) and Verastem (NASDAQ: VSTM). Prior to co-f... 
   Chairperson
Jeffrey D. Capello Financial Expert
Jeffrey D. Capello

Jeffrey D. Capello is the Executive Vice President and Chief Financial Officer of Boston Scientific (NYSE: BSX), a position he has held since March 2010. He is directly responsible for the worldwide management of Boston Scientific's Finance Information Systems, Business Development and Corporate Strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. Prior to joining Boston Scientific, he was the ... 

Chairperson   
Mary Fisher 
Mary Fisher

Ms. Fisher brings more than 25 years of experience in the pharmaceutical and biotechnology industries. Ms. Fisher currently serves as Chief Executive Officer and Director at Colorescience, a former division of SkinMedica, Inc., where she served as Chief Executive Officer from 2008 until 2012, when she led the successful sale of the company to Allergan, Inc. for $375 million. Prior to joining SkinMedica, Ms. Fisher was the Chief Operating Officer of Acorda Therapeutics, where she was responsible ... 
  Committee Member  
John Howe, M.D. 
John Howe, M.D.

Dr. Howe is a recognized expert in international medicine and is a humanitarian leader. From 2001 through 2015, he served as the President and Chief Executive Officer of Project HOPE, an international health education and humanitarian assistance foundation, which operates more than 70 programs in 45 countries on five continents. During Dr. Howe’s tenure, Project HOPE expanded its areas of distributing medicine, treating infectious diseases and non-communicable diseases, and promoting the he... 

Committee Member Committee Member  
Marc Kozin 
Marc Kozin

Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management, both domestically and internationally. Mr. Kozin served as president of the North American practice of L.E.K., a global strategy consulting firm, for 15 years and has been a Senior Advisor to L.E.K. since July 2011. He currently serves as a member of the Board of Directors of UFP Technologies, Inc., DYAX Corp., Endocyte, Inc., and three p... 
   Committee Member
Thomas Malley 
Thomas Malley

Thomas Malley has served on our board of directors since October 2012. He has been President of Mossrock Capital, a private investment firm in Denver, Colorado, since 2007. From 1991 until 2007 Mr. Malley worked at Janus Mutual Funds. From 1999–2007, he started and served as the portfolio manager of the Janus Global Life Sciences Fund, as well as being Vice President in charge of the Janus Healthcare team. From 1991-1998 he served as an equity analyst for Janus covering healthcare and b... 

Committee Member Chairperson